XENE Share Price Performance
US$41.22
2.81 (7.32%)
25.6% undervalued intrinsic discount
US$55.40
Fair Value
Price US$41.22
AnalystConsensusTarget US$55.40
Fair ValueUS$55.40
Share Pricen/a
Xenon Pharmaceuticals Inc. Stock Price
- 1 Narratives written by author
- 0 Comments on narratives written by author
- 4 Fair Values set on narratives written by author
XENE Community Narratives
AN
Fair Value US$55.4 25.6% undervalued intrinsic discount
Epilepsy And Mood Disorder Therapies Will Drive Long-Term CNS Leadership
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
Epilepsy And Mood Disorder Therapies Will Drive Long-Term CNS Leadership
Catalysts About Xenon Pharmaceuticals Xenon Pharmaceuticals is a neuroscience focused biopharma company developing ion channel targeted medicines for epilepsy, mood disorders and pain. What are the underlying business or industry changes driving this perspective?Read more
4
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
US$55.4
25.6% undervalued intrinsic discount
AnalystConsensusTarget's Fair Value
Revenue
236.18% p.a.
Profit Margin
16.03%
Future PE
117.17x
Price in 2028
US$67.3
Trending Discussion
Recently Updated Narratives
AN
Epilepsy And Mood Disorder Therapies Will Drive Long-Term CNS Leadership
Fair Value: US$55.4 25.6% undervalued intrinsic discount
1 followerusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Xenon Pharmaceuticals Inc. Key Details
Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
n/a
- -3.96
- -3,536.15%
- -4,084.45%
- 0%
About XENE
- Founded
- 1996
- Employees
- 322
- CEO
- WebsiteView website
Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders in Canada. Its product candidates include Azetukalner, a selective Kv7 potassium channel opener in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizures, and primary generalized tonic-clonic seizures, as well as neuropsychiatric disorders, such as major depressive disorder and bipolar depression. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a Nav1.2/1.6 sodium channel inhibitor that is in Phase 1 clinical trials for the treatment of certain types of epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.
